NextCure Inc. has announced the closing of a $21.5 million private placement, in which the company sold 708,428 shares of common stock at $8.52 per share and pre-funded warrants to purchase up to 1,815,049 shares of common stock at $8.519 per warrant. The securities were sold in a private placement exempt from SEC registration requirements, with H.C. Wainwright & Co. acting as the exclusive placement agent. The financing was led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management, and will extend NextCure's cash runway into the first half of 2027, supporting ongoing development of its antibody drug conjugate programs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576606-en) on November 17, 2025, and is solely responsible for the information contained therein.